. 2018 Oct 22;178(12):1721–1723. doi: 10.1001/jamainternmed.2018.4846

Table. Quantities of 4 Experimental Stimulants Subject to FDA Public Notices in Supplements Purchased in 2014 and 2017.

Product^a	Claim on Label or Website	BMPEA,^b Mean (SD), mg per Pill or Capsule	1,3-DMAA,^c Mean (SD), mg per Pill or Capsule	DMBA,^d Mean (SD), mg per Pill or Capsule	Oxilofrine,^e Mean (SD), mg per Pill or Capsule
Supplements Purchased in 2014
A	Cognitive function	ND	ND	ND	0.07 (0.04)
B	Weight loss	ND	ND	ND	54.31 (0.82)
C	Weight loss	18.71 (2.16)	36.70 (11.91)^f	ND	34.07 (10.06)
D	Weight loss	5.74 (1.15)	ND	ND	26.48 (2.56)
E	Weight loss	27.35 (5.87)	34.68 (0.89)^f	ND	34.31 (2.06)
F	Weight loss	ND	ND	ND	0.31 (0.04)
G	Sports supplement	3.22 (0.67)	ND	ND	7.78 (0.49)
H	Sports supplement	31.23 (5.72)	ND	ND	31.07 (1.94)
I	Weight loss	9.89 (1.26)	12.17 (1.23)^f	ND	25.62 (1.53)
J	Weight loss	3.35 (0.74)	12.03 (1.31)^f	ND	37.45 (1.21)
K	Weight loss	0.97 (0.31)	11.39 (1.74)^f	ND	40.75 (5.31)
L	Weight loss	23.05 (2.79)	26.89 (6.05)^f	ND	37.44 (7.43)
Supplements Purchased in 2017
A	Cognitive function	ND	ND	ND	0.05 (0.01)^f
B	Weight loss	ND	ND	ND	40.84 (6.48)^f
C	Weight loss	ND	ND	30.43 (3.26)^f	7.09 (0.91)^f
D	Weight loss	ND	ND	ND	28.38 (0.82)^f
E^g	Weight loss	17.23 (1.47)^f	36.12 (5.45)^f	ND	27.43 (1.06)^f
F	Weight loss	ND	ND	ND	ND
G	Sports supplement	ND	ND	ND	ND
H	Sports supplement	ND	ND	ND	ND
I	Weight loss	ND	ND	10.98 (3.09)^f	5.59 (0.85)^f
J	Weight loss	ND	27.99 (1.37)^f	ND	8.77 (0.47)^f
K	Weight loss	ND	ND	17.05 (1.63)^f	8.44 (0.51)^f
L	Weight loss	ND	ND	39.53 (4.39)^f	8.85 (0.81)^f

Abbreviations: BMPEA, indicates β-methylphenylethylamine; DMBA, 1,3-dimethylbutylamine; 1,3-DMAA, 1,3-dimethylamylamine; FDA, US Food and Drug Administration; ND, not detectable.

^{^a}

Coded indicator of the product.

^{^b}

β-Methylphenylethylamine is not approved for use in humans. Quantities of BMPEA in products purchased in 2014 were previously reported.¹

^{^c}

1,3-Dimethylamylamine is a 1940s to 1960s nasal decongestant (Eli Lilly & Co) that was withdrawn from the market in the 1970s. It was never approved for oral use.

^{^d}

1,3-Dimethylbutylamine is not approved for use in humans.

^{^e}

Oxilofrine was previously available in several European countries. It increased blood pressure and cardiac output and was available in 16- to 40-mg capsules. It was never approved for use in the United States.

^{^f}

Quantities represent stimulants in supplements after the FDA issued a public notice about the stimulant. The date of the FDA warning for 1,3-DMAA was July 2013; DMBA, April 2015; BMPEA, April 2015; and oxilofrine (referred to as methylsynephrine), April 2016.

^{^g}

Manufacturer of product E also received an FDA warning letter in 2015 that BMPEA was a prohibited ingredient listed on the label of product E.